Home/Filings/4/0001737287-25-000005
4//SEC Filing

Belldegrun Arie 4

Accession 0001737287-25-000005

CIK 0001737287other

Filed

Jan 27, 7:00 PM ET

Accepted

Jan 28, 8:11 PM ET

Size

321.0 KB

Accession

0001737287-25-000005

Insider Transaction Report

Form 4
Period: 2025-01-24
Transactions
  • Award

    Stock Option (Right to buy)

    2025-01-24+1,307,9271,307,927 total
    Exercise: $1.94Exp: 2035-01-24Common Stock (1,307,927 underlying)
  • Award

    Common Stock

    2025-01-24+369,9572,236,816 total
Holdings
  • Common Stock

    (indirect: See footnote)
    1,798,163
  • Common Stock

    (indirect: See footnote)
    539,867
  • Common Stock

    (indirect: See footnote)
    1,724,137
  • Common Stock

    (indirect: See footnote)
    4,710,120
Footnotes (5)
  • [F1]The securities are held in the name of Bellco Legacy Trust fbo Rebecka Belldegrun, of which the reporting person's spouse is trustee and beneficiary
  • [F2]The securities are held by Vida Ventures LLC (Vida), of which VV Manager LLC is the manager. There porting person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the common shares held by Vida. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
  • [F3]The securities are held by Vida Ventures III, L.P. and Vida Ventures III-A, L.P. Vida Ventures GP III, LLC is the manager of Vida Ventures III, L.P. and Vida Ventures III-A, L.P. The reporting person is a Senior Managing Director of Vida Ventures GP III, LLC and may therefore be deemed to be the beneficial owner of the common shares held by Vida Ventures III, L.P. and Vida Ventures III-A, L.P. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
  • [F4]The securities are held in the name of Bellco Legacy LLC. Bellco Legacy LLC is owned and managed by trusts controlled by the reporting person and Rebecka Belldegrun.
  • [F5]25% of the shares subject to the stock option shall vest on January 24, 2026, and the remaining shares shall vest in 36 equal monthly installments thereafter.

Issuer

Allogene Therapeutics, Inc.

CIK 0001737287

Entity typeother

Related Parties

1
  • filerCIK 0001296549

Filing Metadata

Form type
4
Filed
Jan 27, 7:00 PM ET
Accepted
Jan 28, 8:11 PM ET
Size
321.0 KB